Targeted Market FDA cleared for amblyopia in children over 9 and adults, with CE marking and broad indications, signaling a ready-to-market opportunity across clinics treating vision impairments and pediatric patients.

Clinical Validation Strong clinical performance claims and multiple CPT code approvals by the AMA create credible pain points to present to medical practices and payers, enabling easier reimbursement conversations.

SaaS Upsell As a SaaS-based tool for eye care specialists, there is potential to upsell a recurring software subscription alongside existing services, creating a new revenue stream for clinics and surgery centers.

Expand Clinical Adoption Rapid expansion opportunities with eye care clinics and optometry groups seeking non-invasive, brain-based vision enhancement to differentiate services and reduce post-surgery follow-ups.

Strategic Partnerships Leverage recognition from industry awards and high-profile media coverage to form partnerships with clinics, hospital systems, and payers looking to adopt innovative, non-invasive vision therapies at scale.